News
CANF
1.976
-0.21%
-0.004
Weekly Report: what happened at CANF last week (0415-0419)?
Weekly Report · 1d ago
Can-Fite’s Namodenoson Shows Promise for Liver Cancer
TipRanks · 04/16 01:01
Can-Fite's Namodenoson Featured in Biomedicines for Liver Cancer and MASH Treatment Insights
Can-Fite BioPharma Ltd. Is a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases. Namodenoson is being evaluated in a Phase III study for advanced liver cancer. The journal Biomedicines published an article on the drug's anti-cancer activity and liver protective effects.
Benzinga · 04/15 11:06
Weekly Report: what happened at CANF last week (0408-0412)?
Weekly Report · 04/15 09:33
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Can-Fite BioPharma Ltd. Is advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases. Namodenoson is being evaluated for treatment of liver cancer and metabolic dysfunction-associated steatohepatitis. The drug has been granted Orphan Drug Designation in the U.S. And Europe.
Barchart · 04/15 06:00
Weekly Report: what happened at CANF last week (0401-0405)?
Weekly Report · 04/08 09:35
Can-Fite Advances MASH Treatment into Phase IIb
TipRanks · 04/03 11:59
Can-Fite BioPharma Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Can-Fite BioPharma Ltd. Announced submission of an investigational new drug application to the U.S. Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis. The company is advancing a pipeline of small molecule drugs that address oncological and inflammatory diseases.
Benzinga · 04/03 11:03
BUZZ-U.S. STOCKS ON THE MOVE-Eiger BioPharmaceuticals, Reddit, US energy sector
Stronger-than-expected manufacturing data propped up Treasury yields and tempered expectations of a rate cut in June. The Dow Jones Industrial Average was down 0.75% in midday trading on Monday. The top three S&P 500 percentage gainers were Micron Technology, Wynn Resorts.
Reuters · 04/01 17:47
Weekly Report: what happened at CANF last week (0325-0329)?
Weekly Report · 04/01 09:35
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
TipRanks · 03/29 06:00
Can-Fite BioPharma Reports Reduced Losses in 2023
TipRanks · 03/28 11:59
Can Fite Biofarma: Q4 Earnings Insights
Can Fite Biofarma reported its Q4 earnings on March 28, 2024. The company beat estimates by 96.0%. Can Fite biofarma's revenue was down $42 thousand from the same period last year. Last quarter the company beat on EPS by $0.01.
Benzinga · 03/28 11:50
Can Fite Biofarma FY GAAP EPS $(0.01), Same YoY, Sales $743.00K Down From $810.00K YoY
Benzinga · 03/28 11:23
Can-Fite Biopharma GAAP EPS of -$0.01, revenue of $0.74M
Seeking Alpha · 03/28 11:20
Weekly Report: what happened at CANF last week (0318-0322)?
Weekly Report · 03/25 09:36
Weekly Report: what happened at CANF last week (0311-0315)?
Weekly Report · 03/18 09:35
Can Fite Biophar: Report of foreign issuer
Press release · 03/11 12:03
Weekly Report: what happened at CANF last week (0304-0308)?
Weekly Report · 03/11 09:34
Weekly Report: what happened at CANF last week (0226-0301)?
Weekly Report · 03/04 09:35
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can Fite Biophar through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.